Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 15/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429047 | 0.95 | ALDH1A1 (0.38) | ALDH1A1GAACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6507788 | 0.82 | ALDH1A1 (0.39) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL6426995 | 0.82 | SIGMAR1 (0.30) | — | |
| SCHEMBL6427655 | 0.79 | LMNA (0.36) | CYP3A4CYP2D6CHRM2CHRM4CHRM1 | |
| SCHEMBL6426277 | 0.79 | ALDH1A1 (0.43) | ALDH1A1GAACYP3A4MEN1KMT2A | |
| SCHEMBL6426459 | 0.78 | ACHE (0.36) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL6426125 | 0.75 | EPHX2 (0.33) | ALDH1A1GAA | |
| SCHEMBL1605406 | 0.74 | EPHX2 (0.32) | ALDH1A1GAA | |
| SCHEMBL6429217 | 0.74 | EPHX2 (0.35) | ALDH1A1GAA | |
| SCHEMBL6427323 | 0.74 | DPP4 (0.40) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885GAA 522/4885CYP1A2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.